AKT1 and breast carcinoma: These data verify that interrupting the TRIB3/AKT1 interaction reduces breast cancer stemness and exerts antitumor efficacy by promoting FOXO1 phosphorylation, ubiquitination, and degradation, which suppresses SOX2 expression (Fig. 8g).